Company intelligence / Profile preview

IndieBio

San Francisco, California, United Statesindiebio.co ↗

Ownership: Private
Employees: ~56
Development stage: Other

Overview

As an accelerator program rather than a drug developer or biotech company itself, clinical results are not applicable. However, its alumni have collectively raised billions in follow-on funding and include successful commercial launches in therapeutics and synthetic biology applications.

Therapeutic areas: OncologyRare DiseasesOther
Modalities: Small moleculeBiologicCell therapyGene therapySynthetic biology tools
Industry: Investors

Partnerships

Extensive network with over 400 co-investing venture firmsPartnerships with universities and corporate partners through its alumni network

Beyond the preview

Go deeper on IndieBio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IndieBio.

Explore the full profile